Kalvista Pharmaceuticals Inc (KALV)
$14.82
+0.43
(+2.99%)▲
Live
Performance
- $14.52$14.93$14.82
2.02%
Downside
Day's Volatility :2.75%
Upside
0.74%
- $7.21$16.88$14.82
51.35%
Downside
52 Weeks Volatility :57.29%
Upside
12.2%
Returns
| Period | Kalvista Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 33.49% | 6.5% | 0.0% |
6 Months | 7.63% | 7.1% | 0.0% |
1 Year | 51.31% | 9.8% | 0.0% |
3 Years | -32.22% | 14.2% | -20.2% |
Highlights
Market Capitalization | 616.5M |
Book Value | $4.86 |
Earnings Per Share (EPS) | -3.44 |
PEG Ratio | 0.0 |
Wall Street Target Price | 29.2 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -41.94% |
Return On Equity TTM | -68.9% |
Revenue TTM | 3.8M |
Revenue Per Share TTM | 0.21 |
Quarterly Revenue Growth YOY | 30.7% |
Gross Profit TTM | -80.3M |
EBITDA | -139.6M |
Diluted Eps TTM | -3.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.06 |
EPS Estimate Next Year | -2.56 |
EPS Estimate Current Quarter | -0.73 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 97.03%
Technicals Summary
Sell
Neutral
Buy
Kalvista Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kalvista Pharmaceuticals Inc | 27.23% | 7.63% | 51.31% | -32.22% | -14.95% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals Inc | NA | NA | 0.0 | -3.06 | -0.69 | -0.42 | NA | 4.86 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kalvista Pharmaceuticals Inc | Buy | $616.5M | -14.95% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Kalvista Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 10.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 218.7%
Institutional Holdings
VR Adviser, LLC
14.81%Suvretta Capital Management, LLC
9.94%TANG CAPITAL MANAGEMENT LLC
9.78%Adage Capital Partners Gp LLC
6.10%BlackRock Inc
5.77%Vanguard Group Inc
3.99%
Company Information
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
Organization | Kalvista Pharmaceuticals Inc |
Employees | 150 |
CEO | Mr. Benjamin L. Palleiko |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$14.82
+2.99%
Keyarch Acquisition Corp
$14.82
+2.99%
Connexa Sports Technologies Inc
$14.82
+2.99%
Us Value Etf
$14.82
+2.99%
First Wave Biopharma Inc
$14.82
+2.99%
Global X Msci Next Emerging
$14.82
+2.99%
Fat Projects Acquisition Corp
$14.82
+2.99%
Capital Link Global Fintech
$14.82
+2.99%
Applied Uv Inc
$14.82
+2.99%